Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis - PubMed (original) (raw)
Review
Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis
Leon A Adams et al. J Dig Dis. 2011 Feb.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the USA and many other parts of the world. Its prevalence continues to rise; currently affecting about one in four adults and 10% of children in the USA. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign, no-progressive clinical course, to nonalcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease. Currently, the diagnosis of NASH requires an invasive liver biopsy with drawbacks of sampling and interpretation error. Clinical risk factors for NASH include diabetes and the metabolic syndrome; however, these are not sufficiently predictive of the condition by themselves. Routine liver enzyme levels are not reliable; however, novel plasma hepatocyte cell death markers either alone or in combination with clinical risk factors are potential non-invasive diagnostic tools for the future. This review provides a concise overview of the role non-invasive diagnostic tools for the differentiation of fatty liver from NASH as well as for the determination of presence and extent of fibrosis.
© 2011 The Authors. Journal of Digestive Diseases © 2011 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.
Similar articles
- Nonalcoholic steatohepatitis: risk factors and diagnosis.
Adams LA, Feldstein AE. Adams LA, et al. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):623-35. doi: 10.1586/egh.10.56. Expert Rev Gastroenterol Hepatol. 2010. PMID: 20932147 Review. - Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
Wieckowska A, McCullough AJ, Feldstein AE. Wieckowska A, et al. Hepatology. 2007 Aug;46(2):582-9. doi: 10.1002/hep.21768. Hepatology. 2007. PMID: 17661414 Review. - [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P. Raszeja-Wyszomirska J, et al. Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish. - Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Byrne CD, et al. Clin Sci (Lond). 2009 Apr;116(7):539-64. doi: 10.1042/CS20080253. Clin Sci (Lond). 2009. PMID: 19243311 Review. - Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.
Wieckowska A, Feldstein AE. Wieckowska A, et al. Semin Liver Dis. 2008 Nov;28(4):386-95. doi: 10.1055/s-0028-1091983. Epub 2008 Oct 27. Semin Liver Dis. 2008. PMID: 18956295 Review.
Cited by
- Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery.
Yuan X, Chen J, Cheng Q, Zhao Y, Zhang P, Shao X, Bi Y, Shi X, Ding Y, Sun X, Xue B. Yuan X, et al. BMC Gastroenterol. 2018 Oct 3;18(1):147. doi: 10.1186/s12876-018-0871-2. BMC Gastroenterol. 2018. PMID: 30285651 Free PMC article. - Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.
Fitzpatrick E, Dhawan A. Fitzpatrick E, et al. World J Gastroenterol. 2014 Aug 21;20(31):10851-63. doi: 10.3748/wjg.v20.i31.10851. World J Gastroenterol. 2014. PMID: 25152587 Free PMC article. Review. - Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan.
Tuong TTK, Tran DK, Phu PQT, Hong TND, Dinh TC, Chu DT. Tuong TTK, et al. Diagnostics (Basel). 2020 Mar 14;10(3):159. doi: 10.3390/diagnostics10030159. Diagnostics (Basel). 2020. PMID: 32183383 Free PMC article. - Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Lin SC, Heba E, Bettencourt R, Lin GY, Valasek MA, Lunde O, Hamilton G, Sirlin CB, Loomba R. Lin SC, et al. Aliment Pharmacol Ther. 2017 Mar;45(6):844-854. doi: 10.1111/apt.13951. Epub 2017 Jan 24. Aliment Pharmacol Ther. 2017. PMID: 28116801 Free PMC article. Clinical Trial. - The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.
Pagadala MR, McCullough AJ. Pagadala MR, et al. Clin Liver Dis. 2012 Aug;16(3):487-504. doi: 10.1016/j.cld.2012.05.006. Epub 2012 Jun 27. Clin Liver Dis. 2012. PMID: 22824477 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources